Randall A. Oyer, MD, explains the immunotherapy data coming out of the Annual Meeting 2018 and the purpose of the…
Browsing: General
Ivo Abraham, PhD, RN, shares his thoughts on demonstrating the value of cancer care in today’s oncology landscape at Annual…
Ivo Abraham, PhD, RN, shares his perspective on biosimilar pricing and reimbursement at Annual Meeting 2018.
Randall A. Oyer, MD, explains how ACCC is utilizing the data on genetics presented at the 2018 Annual Meeting Annual…
Ivo Abraham, PhD, RN, talks about biosimilars that are approved or close to approval at Annual Meeting 2018.
Ghassan Abou-Alfa, MD, MBA, explains the shortcomings of the RECIST study in measuring efficacy in hepatocellular carcinoma (HCC) patients at…
Stephen Devereux, FRCP, FRCPath, PhD, of Kings College Hospital NHS Foundation Trust, London, UK gives his highlights from the the…
The 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, proved to be an exciting…
Jennie Crews, MD, MMM, FACP, talks about key initiatives for the ACCC Immuno-Oncology Institute at Annual Meeting 2018
Ghassan Abou-Alfa, MD, MBA, explains the outcomes of the CELESTIAL study from Annual Meeting 2018.
Ivo Abraham, PhD, RN, shares his thoughts on demonstrating the value of cancer care in today’s oncology landscape at Annual…
Jennie Crews, MD, MMM, FACP, discusses the mission of the ACCC Immuno-Oncology Institute at Annual Meeting 2018.
Ghassan Abou-Alfa, MD, MBA, explains how immunotherapies should be combined with TKIs at Annual Meeting 2018.
Ivo Abraham, PhD, RN, explains the key characteristics of a biosimilar at Annual Meeting 2018.
Jennie Crews, MD, MMM, FACP, talks about how community oncology is interpreting and incorporating biomarkers into their immuno-oncology therapeutic choices
Ghassan Abou-Alfa, MD, MBA, talks about the latest in systemic therapy for advanced hepatocellular carcinoma (HCC) at the 2018 Annual…
Although clinical trials provide us with an abundance of useful data, some of this may not be optimal for application…
Mick Peake, MD, of the University of Leicester, Leicester, UK, discusses the Collaboration for Oncology Data in Europe (CODE); an…
In this video, Mick Peake, MD, of the University of Leicester, Leicester, UK, notes the importance of collating information regarding…
Joan Schiller, MD, shares the validity of Tumor Mutation Burden (TMB) as a biomarker at Annual Meeting 2018.
Joan Schiller, MD, shares Keynote trials & the influence on choice of therapy from Annual Meeting 2018.
Treatment options for gynecological cancers have become more effective and diverse in the last few decades. In this video, Marcia…
Speaking at the UK Oncology Forum (OF) 2018, held in Liverpool, UK, Dr Woolmore, Initiative Lead, Collaboration for Oncology Data…
Immunotherapy has huge potential for treating a wide variety of cancer types. In this video, recorded at the UK Oncology…
The RANGO project aims to create a database for rare gynecological tumors in order to facilitate improved disease understanding and…
Much of the focus for immunotherapy research is on the cancers for which it works best, such as Hodgkin lymphoma…
Collaboration for Oncology Data in Europe (CODE) is a collaborative network that aims to promote the sharing of research data…
Quality of life and symptom data are essential for informing treatment plans as a clinician, as Esther Oliva, MD, of…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Fabio Guolo, MD, of…
The European Hematology Association (EHA) Scientific Working Group on Aging and Hematology released a new edition about geriatric oncology. Here,…
Chimeric antigen receptor (CAR) T-cells have been a key focus in cancer research over recent years; however, T-cells are not…
Bobby Green, MD, explains Flatiron’s clinico-genomic database helping shed light on the cost-effectiveness of next-generation sequencing.
Bobby Green, MD, explains Flatirons clinico-genomic database and how it may be used to direct treatments.
Roy S. Herbst, MD, PhD, talks about Exciting developments from the 2018 Annual Meeting.
Bobby Green, MD, shares what people will most likely be talking about from the 2018 Annual Meeting.
Edgardo S. Santos, MD, FACP, shares exciting developments coming out of the 2018 Annual Meeting
Patient-reported outcomes (PROs) give a greater insight into the lives of patients and their perspectives on the treatment received. Here,…
Speaking at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Paul Richardson, MD,…
Willem Ouwehand, MD, PhD, of the University of Cambridge, Cambridge, UK, discusses non-malignant hematology, particularly rare inherited disorders of hematopoietic…
HaemSTAR is a network of clinical hematology registrars within the UK that aims to promote clinical research in non-malignant hematology.…
A large proportion of gynecological tumors are classed as rare tumors because of their variable morphologies and pathologies. We interviewed…
In this Virtual Patient Case, renown clinical expert Dr. Martyn Caplin utilizes a follow-up clinical scenario to elucidate the latest…
In this Virtual Patient Case, renown clinical expert Dr. Martyn Caplin utilizes a clinical scenario to elucidate the latest advances…
Collaboration for Oncology Data in Europe (CODE) is an alliance that brings together patient associations, charities and treatment centers in…
The integration of scientific research into clinical practice is one of the many challenges healthcare professionals face. Here, Mariam Jamal-Hanj,…
Voluntary, non-remunerated blood donations are uncommon in developing countries and ethnic minority populations. Kenneth Charles, MBBS, FRCP, FRCPath(Haem), from the…
At the UK Oncology Forum (OF) 2018, held in Liverpool, UK, Steve Williamson, from Northumbria NHS Foundation Trust, Newcastle upon…
Andrew Armstrong, MD, from Duke University, Durham, NC, speaks from the 2018 American Society of Oncology (ASCO) Annual Meeting, held…
The next 4 years are going to be exciting and productive for transplant research across a broad range of hematological…
In this interview, David Avigan, MD, from Beth Israel Deaconess Medical Centre, Boston, MA, discusses the exciting therapeutic area of…
Venous thromboembolism (VTE) effects 20% of all cancer patients. In this interview with Cihan Ay, MD, from the Medical University…
Physicians may encounter difficulties integrating proton beam therapy amongst existing radiotherapy options. Here, Neil Burnet, MA, MBBChir, FRCR, MD, of…
The introduction of proton beam therapy has brought with it a multitude of implications, which Neil Burnet, MA, MBBChir, FRCR,…
As Chair of the meeting, Ruth Plummer, MD, of Newcastle University, Newcastle, UK, give us her overview of the highlights…
At the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK, Anita Hill, MBChB (Hons), MRCP,…
Thrombosis is the leading cause of morbidity and mortality in paroxysmal nocturnal hemoglobinuria (PNH). In this interview, Anita Hill, MBChB…
The Systemic Anti-Cancer Therapy (SACT) Competency Passport, produced by leading cancer nuses in partnership with the UK Oncology Nursing Society…
How to maintain optimal patient safety and wellbeing is a constant concern and priority for healthcare professionals. At the UK…
Gerry Hanna, MD, from Queens University Belfast, Belfast, UK, provides an insight into the two new landmark platforms investigating radiotherapy-drug…
CT scans are currently the standard for mapping targeted areas for cancer treatment; however, MRI has been shown to produce…
With the increasing life expectancy of cancer patients, the long-term consequences of cancer therapy are becoming an increasing issue. Anthracycline-induced…
Here, Jacob Kettle, PharmD, BCOP, of the University of Missouri Health Care, Columbia, MO, shares his perspective on the different…
Jacob Kettle, PharmD, BCOP, of the University of Missouri Health Care, Columbia, MO, discusses the different ways in which pharmacists…
In this interview, Christopher Campen, PharmD, BCOP, from the GHS Cancer Institute, Greenville, SC, discusses combining immune checkpoint inhibitors for…
The unique side effects that accompany the use of immune checkpoint inhibitors for the treatment of cancer need to be…
Patient-reported outcomes (PROs) give a greater insight into the lives of patients and their perspectives on the treatment received. Here,…
The expression of programmed death-ligand 1 (PD-L1) can be used as a clinical biomarker to determine the efficacy of immune…
Immune checkpoint inhibitors are effective in the management of various cancers. However, there are a number of side effects that…
Emily L. Harris, Ph.D., M.P.H.,National Cancer Institute – Deputy Associate Director, explains ARA Process for Large Budget Grants Program director…
Elaine R. Mardis, PhD, The Institute for Genomic Medicine, talks Cancer Care for Pediatctrics and Young Adults Rare diseases in…
Elaine R. Mardis, PhD, The Institute for Genomic Medicine, talks about Variety of Developments in Cancer Genomics Translate discoveries in…
Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, FDA Approval of Pembrolizumab The 1st approval of a drug that is…
How Do Thoracic Surgeons Assess Fitness for Surgery
Dr. David Harpole, Duke University Medical Center, describes the mediastinoscopy and its use in lung cancer staging.
Dr. David Harpole, Duke University Medical Center, describes the sleeve resection and how it can help selected patients with large…
Dr. David Harpole, Duke University Medical Center, defines the concept of mediastinal node sterilization and its use after neoadjuvant therapy.
Dr. David Harpole, Duke University Medical Center, compares traditional open thoracotomy with video-assisted thorascopic surgery, highlighting the advantages of the…
How Rate of Progression Can Affect Treatment Decisions
Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.
Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.
Dr. Ross Camidge, University of Colorado, discusses the potential benefits as well as the disadvantages of multiplex mutation testing.
Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.
Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and…
Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment…
Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first…
Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology
Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.
Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in…
2nd video in GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and…
4th video in GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and…
Dr. Rachel Sanborn, Providence Thoracic Oncology Program, discusses using adjuvant chemotherapy for elderly and frail patients. What was seen in…
On August 20, 2016, in collaboration with the University of Colorado Cancer Center, GRACE presented the Targeted Therapies in Lung…
GRACE is happy to present the 9th and final video in our series ASCO 2016 Lung Cancer Roundtable, Highlights and…
Jose F. Leis, MD, PhD, explains how Control of disease can be achieved with Ibrutnib High-risk Relapsed Refractory patients will…
Richard R. Furman, MD, talks about how MBL Patients Don’t Need Bone Marrow Biopsies MBL can be followed by CBCs…
Jose F. Leis, MD, PhD, explains Venetoclax Rapidly Moving as Best 2nd-line Therapy SCT still remains as the only curative…
Matthew S. Davids, MD, MMSc, talks about how Venetoclax w Rituximab progressed the furthest Phase 3 Data shows the combination…
Richard R. Furman, MD, talks about how MBL Patients Don’t Need Bone Marrow Biopsies MBL can be followed by CBCs…
Jose F. Leis, MD, PhD, explains PET-Scans Not as Specific for Richter’s Transformation Biopsies are essential for those who fail…
Amer M Zeidan, MBBS, talks about A lot of Questions on the Best Use of New Drugs Still waiting on…
Matthew S. Davids, MD, MMSc, explains Role of Chimeric Antigen Receptor T Cells CAR-T Cell after multiple novel agent-based therapies…
Richard M. Stone, MD, talks about Incorporating Midostaurin for FLT3 Positive Patients Use Gemtuzumab Ozogamicin for CD33 Expression at Imedex…
GRACE is happy to present the 7th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in…
http://cancerGRACE.org/
GRACE is happy to present the 5th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in…
3rd video in GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and…
In this sixth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the breakout…
In this eighth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the lunchtime…
Dr. Rafael Santana-Davila, Assistant Professor of Medicine at the University of Washington, Seattle Cancer Care Alliance joined GRACE to share…
In this tenth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon…
In this twelfth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon…